PTSD News

On April 5, a 4.8-magnitude earthquake shook the Northeast region of the United States, an “infrequent but not unexpected” event for this part of the country, according to the U.S. Geological Survey.

The risk for mental health conditions and self-harm or suicide was higher among partners and adult offspring of stroke survivors vs. the general population and family of myocardial infarction survivors, according to a study in Denmark.

After first-time stroke, comorbid PTSD was associated with increased risk for hospital readmission among Black veterans that was not observed among white veterans, researchers reported.

Brief psychological therapies delivered soon after traumatic childbirth may provide an opportunity to protect against childbirth-related PTSD symptoms, researchers reported.

Crisis response planning, a therapist-guided treatment for suicidal ideation, significantly reduced symptoms of suicidal ideation among U.S. military personnel and veterans, according to a study published in Journal of Anxiety Disorders.

The FDA has accepted and granted priority review to a new drug application for midomafetamine capsules used in combination with psychological intervention for PTSD, according to a press release from Lykos Therapeutics.

Patients who are hospitalized with stroke-like symptoms, but do not experience a stroke, may yet develop PTSD at a higher rate than patients who actually had a stroke, a speaker reported.

The American Psychiatric Association has selected Marketa Wills, MD, MBA, as its new CEO and medical director, effective June 1.

Silo Pharma will advance a portfolio of four drugs in its 2024 clinical pipeline, targeting conditions related to mental health, chronic pain and neurology.

A Houston-based neurohealth company has received a patent for its non-invasive, frequency-based deep brain stimulation device to address a range of psychiatric and neurologic conditions.